Drugs / TX000045
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07473700 | Mar 2026 → Nov 2027 expected | interstitial lung disease, pulmonary hypertension | Tectonic Operating Company, Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06616974 | Sep 2024 → Nov 2026 expected | heart failure, pulmonary hypertension | Tectonic Therapeutic | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TX000045 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07473700 ↗ |
| Route | Subcutaneous | “The participants will receive a subcutaneous injection of Dose A of TX000045 every 2 weeks for 24 weeks.” NCT06616974 ↗ |